Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Study Comparing Discovery Labs' Surfaxin(R) vs. Curosurf(R) Published in Pediatric Research
Date : 09/22/2010 @ 7:00AM
Source : GlobeNewswire Inc.
Stock : Discovery Laboratories, Inc. (DSCO)
http://ih.advfn.com/p.php?pid=nmona&article=44473328&symbol=DSCO
Discovery Laboratories, Inc. (Nasdaq:DSCO) announces that new data from a pre-clinical study regarding Surfaxin® (lucinactant) was recently published in Pediatric Research. The study was conducted at Loma Linda University using the preterm lamb model which is recognized by the neonatal academic community as a well-established pre-clinical model of human respiratory distress syndrome (RDS). The results of the study demonstrate that lung function following Surfaxin exposure compares favorably to Curosurf®, an animal-derived and current market leading surfactant, when administered to surfactant-deficient preterm lambs. Additionally, pulmonary distribution of surfactant was significantly improved with Surfaxin when compared with that of Curosurf in this study.
Dr. Thomas F. Miller, Chief Operating Officer of Discovery Labs, commented, "In this study, Dr. Terry and colleagues observed a significantly improved lung-distribution profile favoring Surfaxin versus Curosurf, supporting a potential advantaged dosing-volume strategy to protect the lungs of RDS infants. We are pleased with the continued interest of the academic neonatology community in our novel surfactant technology platform and we are fortunate to collaborate with such well-respected thought leaders as those at Loma Linda University."
Pediatric Research is a prominent peer-reviewed journal that publishes results of significant clinical and laboratory studies intended for research-oriented pediatricians. The published manuscript is:
Pulmonary Distribution of Lucinactant and Poractant Alfa and Their Peridosing Hemodynamic Effects in a Preterm Lamb Model of Respiratory Distress Syndrome (Terry et al.) Pediatric Research 68: 193-198, 2010.
The objective of the study was to compare responses to two surfactants with different dose volumes (Surfaxin 5.8 mL/kg and Curosurf 2.5 mL/kg) given to newly-delivered preterm lambs with established RDS. Both surfactants improved lung function and oxygenation, with stable blood pressure and no significant changes in cerebral blood flow. Intrapulmonary distribution of surfactant was significantly improved with Surfaxin (p < 0.05) compared to Curosurf when assessed with an established methodology.
About Surfaxin
Discovery's Labs' surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, a substance produced naturally in human lungs and essential for breathing. If approved, Surfaxin would be the first synthetic, peptide-containing surfactant available for commercial use in neonatal medicine. The safety and efficacy of Surfaxin for neonatal RDS has been previously demonstrated in a Phase 3 clinical program. Surfaxin is currently under review by the U.S. Food and Drug Administration (FDA) for potential marketing approval for the prevention of RDS in premature infants and is the subject of a Complete Response Letter. The Company believes that it remains on track to submit a complete response to the FDA in the first quarter of 2011, potentially leading to Surfaxin approval that year.
Surfaxin is an investigational drug product that has not been approved by the FDA or any other world health regulatory authority. The study results reported above include information that may be of interest to healthcare practitioners; however, the clinical relevance of these results has not been fully established and further scientific investigation may be warranted.
About Pediatric Research
Pediatric Research presents the work of leading authorities in pediatric pulmonology, neonatology, cardiology, hematology, neurology, developmental biology, fetal physiology, endocrinology and metabolism, gastroenterology, and nutrition. Directed to research-oriented pediatricians and faculty, the journal publishes the results of significant clinical and laboratory studies. The Journal includes original peer-reviewed articles, abstracts of society meetings, state-of-the-art reviews, as well as supplements on pediatric health issues. Pediatric Research is the official publication of the American Pediatric Society, the European Society for Paediatric Research, and the Society for Pediatric Research.
About Discovery Labs
Discovery Laboratories, Inc. is a biotechnology company developing KL4 surfactant therapies for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, aerosol or lyophilized formulations. In addition, Discovery Labs' proprietary capillary aerosolization technology produces a dense aerosol, with a defined particle size that is capable of potentially delivering aerosolized KL4 surfactant to the deep lung without the complications currently associated with liquid surfactant administration. Discovery Labs believes that its proprietary technology platform makes it possible, for the first time, to develop a significant pipeline of surfactant products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.Discoverylabs.com.
Forward Looking Statements
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Examples of such risks and uncertainties, including those related to the Company's pre-clinical and clinical research and development activities, are described in Discovery Labs' filings with the Securities and Exchange Commission including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.
CONTACT: Linnden Communications
Media relations:
Michelle Linn
508-362-3087
Discovery Laboratories, Inc.
Investor relations:
John G. Cooper, President and Chief Financial Officer
215-488-9490
Apricus Bio Receives FDA Guidance on Phase 3 Study Design for RayVa™ Treatment for Raynaud’s Syndrome, Secondary to Scleroderma
Date : 09/21/2010 @ 3:11PM
Source : Business Wire
Stock : Apricus Biosciences (APRI)
http://ih.advfn.com/p.php?pid=nmona&article=44463472&symbol=N^APRI
Apricus Biosciences (“Apricus Bio”) (Nasdaq: APRI), backed by a revenue-generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, announced today that the U.S. Food and Drug Administration (FDA) has provided guidance on the clinical requirements for assessing the approvability of RayVa for the treatment of Raynaud’s syndrome secondary to scleroderma. The Company met with FDA officials, including the Director of the Cardiovascular Division, in an effort to gain a clear and defined clinical path to support an application for the approval of RayVa. In the meeting, the FDA officials agreed with the Company on the clinical endpoints and agreed to receive a Phase 3 Special Protocol Assessment (“SPA”) clinical trial protocol for review. The Company is currently working to finalize and submit the Phase 3 SPA protocol, which the FDA will then have 30 days to review before human clinical studies are allowed to commence.
Raynaud's syndrome is a disorder in which the fingers or toes (digits) suddenly experience decreased blood circulation, and is characterized by color changes of the skin of the digits upon exposure to cold or emotional stress. Patients with Raynaud’s syndrome secondary to scleroderma typically have more severe complications, including digital ulcers. The prevalence of Raynaud's syndrome in the general U.S. population is estimated to vary from 4–15%. Females are seven times more likely to develop the condition than men. For most patients, Raynaud’s syndrome is an inconvenience. However, chronic recurrent cases of Raynaud’s syndrome can result in atrophy of the skin, subcutaneous tissues and muscle. In rare cases, it can cause ulceration and ischemic gangrene.
Commenting on today’s news, Bassam Damaj, Ph.D., President and Chief Executive Officer of Apricus Bio, stated, “We are currently in the process of completing and submitting the final protocol for this trial. We believe that our success in obtaining approval to submit a Phase 3 SPA protocol to the agency further demonstrates the favorable safety profile of NexACT as observed in our clinical trials conducted to date. We now look forward to pursuing and commencing discussions for potential development partners for RayVa in the months to come with the objective of finding a development partner who will help to fund the expected costs of the RayVa study.”
About Apricus Biosciences
Backed by NexMed, USA and Bio-Quant, Inc., its revenue generating CRO business, Apricus Bio has leveraged the flexibility of its proven NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth is expected to be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. For further information on Apricus Bio and its subsidiaries, visit http://www.apricusbio.com. (Apricus Bio was previously named NexMed, Inc. The corporate name was changed in September 2010 in recognition of the evolution and expansion of the Company’s business.)
Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including but not limited to its ability to replicate pre-clinical results in human clinical trials, enter into partnership agreements for the Company’s drug candidates or technologies, and obtain regulatory approval for any product candidates in development. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s most recent annual report on Form 10-K and subsequent quarterly reports filed on Form 10-Q. Copies of these reports are available from the SEC’s website or without charge from the Company.
Discovery Labs Appoints Thomas C. Hoy as Vice President of Manufacturing Operations
Date : 09/21/2010 @ 7:30AM
Source : GlobeNewswire Inc.
Stock : Discovery Laboratories, Inc. (DSCO)
http://ih.advfn.com/p.php?pid=nmona&article=44454256&symbol=DSCO
Discovery Laboratories, Inc. (Nasdaq:DSCO), has today announced the appointment of Thomas C. Hoy as Vice President, Manufacturing Operations. Mr. Hoy will be directly responsible for leadership and management of all Discovery Labs' KL4 surfactant product manufacturing, global supply chain, and pharmaceutical development of Discovery Labs' surfactant replacement therapy products, Surfaxin®, Surfaxin LSTM and Aerosurf®. In a related matter, on September 15, 2010, Charles F. Katzer, Senior Vice President, Chief Technical Officer, resigned to pursue another opportunity.
Mr. Hoy brings significant experience in product manufacturing, including over 20 years at Johnson & Johnson (J&J). He has particular experience in sterile pharmaceutical manufacturing of complex biologic molecules, both in-house and at Contract Manufacturing Organizations (CMOs), and has successfully lead teams through facility regulatory inspections by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). At J&J, Mr. Hoy served as General Manager, Global Biologics Supply Chain, where he was responsible for a 400-person bulk biologic production facility for the manufacturing of a finished product that produced over $1 billion in sales, and as General Manager, Contract Operations for Global Biologics Supply. Prior to his appointment as General Manager, Mr. Hoy held positions of increasing responsibility within the manufacturing organizations of J&J. Earlier in his career, Mr. Hoy was involved in pharmaceutical development and aseptic manufacturing. Mr. Hoy is a registered pharmacist and received his pharmacy degree from the Philadelphia College of Pharmacy and Science and a MBA degree from Drexel University.
Thomas Hoy commented, "I am excited to be joining the team at Discovery Labs at this time. The KL4 surfactant technology platform has the potential to meaningfully impact the standard of respiratory critical care. I am impressed with the manufacturing team and their accomplishments and look forward to working with management towards the goal of FDA approval of Surfaxin for the prevention of respiratory distress syndrome (RDS) in premature infants in 2011."
Mr. W. Thomas Amick, Chairman of the Board and Interim Chief Executive Officer of Discovery Labs commented, "We are at an important inflection point at Discovery Labs, as we prepare for a potential filing in the first quarter 2011 of our Surfaxin Complete Response, the potential US approval for Surfaxin and initiation of Surfaxin product supply later in the year. I have extensive, direct experience working with Tom in senior manufacturing roles at J&J, and I am confident that he will successfully lead Discovery Labs' manufacturing team through these pending milestones. I also would like to thank Chuck Katzer for his contributions throughout his tenure at Discovery Labs, including the development of an in-house KL4 surfactant manufacturing capability, oversight of prior successful FDA facility inspections, establishment of our surfactant aerosolization technology development competency and recent initiation of a technology transfer to our CMO for Surfaxin LS production."
About Discovery Labs
Discovery Laboratories, Inc. is a biotechnology company developing KL4 surfactant therapies for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, aerosol or lyophilized formulations. In addition, Discovery Labs' proprietary capillary aerosolization technology produces a dense aerosol, with a defined particle size that is capable of potentially delivering aerosolized KL4 surfactant to the deep lung without the complications currently associated with liquid surfactant administration. Discovery Labs believes that its proprietary technology platform makes it possible, for the first time, to develop a significant pipeline of surfactant products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.Discoverylabs.com.
Forward Looking Statements
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including with respect to the potential approval in the United States of Surfaxin for the prevention of RDS in premature infants and the potential of Discovery Labs' KL4 surfactant technology platform to meaningfully impact the standard of respiratory critical care, are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Examples of such risks and uncertainties are described in Discovery Labs' filings with the Securities and Exchange Commission including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.
CONTACT: Linnden Communications
Media relations:
Michelle Linn
508-362-3087
Discovery Laboratories, Inc.
Investor relations:
John G. Cooper, President and Chief Financial Officer
215-488-9490
Zoom Technologies Receives Additional Orders From Beijing Tianyu
Date : 09/21/2010 @ 7:30AM
Source : MarketWire
Stock : Zoom Technologies (ZOOM)
http://ih.advfn.com/p.php?pid=nmona&article=44454288&symbol=ZOOM
Zoom Technologies, Inc. (NASDAQ: ZOOM), a leading China based manufacturer of mobile phones and related products, today announced it has received an increase in orders from Beijing Tianyu, its largest EMS customers. Beginning in the fourth quarter of 2010, Beijing Tianyu will increase its orders by an additional 500,000 units per month, or 1.5 million units per quarter, when fully ramped. Before the increase, Zoom's orders from Beijing Tianyu were about 2.2 million units per quarter, comprising of approximately half in PCBA (main circuitry) units and half in whole mobile phones.
Mr. Lei Gu, Chairman and Chief Executive Officer of Zoom Technologies, stated, "The increase in mobile phones manufactured by Zoom Technologies directly reflects the strength of the Chinese macroeconomic environment, the robust mobile phone industry and Zoom's strategy to gain market share. We highly value the confidence Tianyu has expressed in Zoom Technologies and we share the same goals of expansion and technology development. Also propelling Zoom's market opportunity is China's low penetration rate in mobile phone usage of only 55%, as compared to over 90% in many developed countries."
About Zoom Technologies
Zoom Technologies is a holding company with subsidiaries that engage in the manufacturing, research and development, and sale of electronic and telecommunication products for 3rd generation mobile phones, wireless communication circuitry, and related software products. Zoom Technologies' subsidiary, Jiangsu Leimone, owns a majority stake of TCB Digital, which offers highly customized and high quality Electronic Manufacturing Service (EMS) for Original Equipment Manufacturer (OEM) customers as well as its Own Brand Manufacturing (OBM) under the brand name of Leimone. The company's products are both exported and sold domestically.
Forward-Looking Statements
Certain statements in this press release may constitute "forward looking statements" that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events. You should not place undue reliance on these forward-looking statements. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly release revisions to these forward-looking statements to reflect future events or circumstances or reflect the occurrence of unanticipated events.
Investor Relations Contact:
Cynthia Hiponia
The Blueshirt Group
415-217-4966
Apricus Bio Announces Confirmatory Results Qualifying NexACT as an Anti-Microbial Preservative
Date : 09/20/2010 @ 11:00AM
Source : Business Wire
Stock : Apricus Biosciences (APRI)
http://ih.advfn.com/p.php?pid=nmona&article=44440577&symbol=N^APRI
Apricus Biosciences (“Apricus Bio”) (Nasdaq: APRI), backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, today announced that results from a United States Pharmacopeia Preservative Efficacy Test (USP PET) qualified NexACT as an anti-microbial preservative. The results show that NexACT was effective in killing more than 23 strains of bacteria, fungus and mold, well beyond the requirements for passing the USP PET. These results are supported by the Company’s prior, long-term stability and microbiology data, generated from its clinical batches of Vitaros® (Apricus Bio’s topical treatment for erectile dysfunction).
Commenting on today’s news, Bassam Damaj, Ph.D., President and Chief Executive Officer of Apricus Bio, stated, “The ability of NexACT to function as a preservative opens up new partnering opportunities with pharmaceutical and cosmetic developers. The safety of NexACT has been tested extensively in over 4,500 patients to date, with excellent results. We therefore think it has the potential to compete with commonly used preservatives, such as parabens, which are in more than 90 percent of all marketed cosmetic products and can cause allergic reactions such as contact dermatitis and delayed hypersensitivity reaction in about 10% of the population. We look forward to publishing this data and sharing our findings with potential partners.”
About Apricus Biosciences
Backed by NexMed, USA and Bio-Quant, Inc., its revenue generating CRO business, Apricus Bio has leveraged the flexibility of its proven NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth is expected to be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. For further information on Apricus Bio and its subsidiaries, visit http://www.apricusbio.com. (Apricus Bio was previously named NexMed, Inc. The corporate name was changed in September 2010 in recognition of the evolution and expansion of the Company’s business.)
Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including but not limited to, its ability to replicate laboratory results in commercial production, enter into partnership agreements and successfully execute business plans. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s most recent annual report on Form 10-K and subsequent quarterly reports filed on Form 10-Q. Copies of these reports are available from the SEC’s website or without charge from the Company.
Keryx Remains a Focused, Well-Funded Bio-Pharma Play
by: Mike Havrilla September 19, 2010
http://seekingalpha.com/article/225946-keryx-remains-a-focused-well-funded-bio-pharma-play?source=feed
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is an emerging, small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex) under Special Protocol Assessment (SPA) agreements with the FDA. I initially wrote about KERX in January 2010, and the Company has performed well (with stock price doubling from approx. $2.50 to $5.00 per share) thanks to delivering on its strategic objectives of advancing its lead compounds into three pivotal Phase 3 studies - with Phase 3 results expected for Zerenex in about three months (December timeframe).
KERX is well capitalized with no debt/convertibles and approximately $32 million in cash/equivalents as of 6/30/10. In addition, the Company has about 59 million shares of common stock outstanding with a fully diluted share count of 70 million and average daily trading volume that has grown over the past year to over 1 million shares per day. The expected cash burn rate for KERX during 2H10 is approximately $10 million, which will be offset by the same amount in expected milestone payments over the next six months that include option/warrant exercises and a milestone payment from its Zerenex partner in Japan (JT Torii) upon initiation of a pivotal Phase 3 study.
KERX has retained all key commercial rights for its two lead compounds and has the resources to complete Phase 3 development for both of its lead compounds, which provides more leverage in partnership discussions. Below is an outline of the two lead compounds and three ongoing pivotal Phase 3 studies for KERX.
Zerenex (ferric citrate) (an iron-based phosphate binder to treat elevated phosphorus blood levels in dialysis patients) - has out-licensed rights to JT Torii in China, Taiwan, Korea, and Japan.
Initiated short-term efficacy study 5/6/10 with top-line results expected in Dec. 2010, long-term safety plus efficacy study (58-week study in approx. 300 patients) expected to begin in Sept. or Oct. 2010 with data anticipated during 1H12, Japan Partner (JT Torii) Phase 3 pivotal study expected to begin by year-end 2010 (a mid-single digit million dollar milestone payment is due to KERX once started). An additional $15 million milestone is possible upon regulatory approval in Japan, with approximately $55 million in remaining milestone payments based on the achievement of sales targets upon commercialization.
Perifosine (KRX-0401) (PI3K/Akt pathway inhibitor anti-cancer agent) - has in-licensed the North American rights to this compound from Aeterna Zentaris (NASDAQ:AEZS) as part of a milestone-based plus royalty agreement - Pivotal Phase 3 Clinical Trials under SPA.
Refractory metastatic colorectal cancer (mCRC) study initiated 4/8/10, patient enrollment (430 patients) expected to conclude in 12-14 months, study completion and top-line results projected during 2H11, announced Fast Track designation by FDA for mCRC on 4/5/10.
Relapsed or relapsed/refractory multiple myeloma (MM) patient study began Dec. 2009, patient recruitment (400 patients) expected to conclude in 16-18 months, study completion and top-line results projected during 1H12, FDA Orphan Drug/Fast Track status.
Zerenex works by forming iron-phosphate complexes in the gut that are not absorbed since patients with end-stage renal disease (ESRD) are prone to electrolyte disorders such as elevated phosphorus due to the absence of normal kidney function. Zerenex represents a niche market opportunity within a well-understood/established class of drugs (phosphate binders) that has a key differentiation of being iron-based compared to existing treatments such as PhosLo, Fosrenol, and Renagel/Renvela. In addition, Zerenex has the potential to offer an improved safety profile/patient acceptance with reduced GI/bloating side effects and approximately 50% less dosing burden (i.e. taking less pills less often) compared to existing phosphate binders.
Secondary endpoints that will be evaluated in the upcoming long-term study for Zerenex include the potential to increase iron levels and decrease the need for blood cell stimulators EPO agents such as Epogen and Aranesp), which could result in a first-line phosphate binder indication and pharmaco-economic advantages by reducing the need for IV iron/EPO products in dialysis patients. The global market for phosphate binders is over $1 billion and is dominated by Genzyme (NASDAQ: GENZ), which markets both Renagel and Renvela that control a market share of approximated one-half of all prescriptions and over two-thirds of global sales (over $700 million for these two drugs).
As I wrote in January, KERX remains a focused, well-funded small-cap bio-pharma play that has three ongoing Phase 3 studies under SPA for its two lead compounds with results pending in about three months (December) for Zerenex in the short-term efficacy study and initiation of the long-term study in the near-term. Perifosine remains a major catalyst in 2011 with Phase 3 data from the colon cancer study expected in about one year (2H11), and KERX has adequate funding to fully develop both of its lead compounds with additional potential for partnership/licensing opportunities for the North American rights to perifosine and ex-Asia rights to Zerenex.
From a trading/investing standpoint, I am currently tracking KERX on my watch list and will be looking to buy on any pullbacks (as stock price has risen sharply recently) ahead of the Phase 3 results for Zerenex in December, which have an excellent chance of meeting all endpoints based on positive results achieved to date in Phase 2 trials and the straightforward mechanism of binding phosphate to lower blood levels in patients with kidney disease.
Disclosure: No positions
MDW - pre $.66 (+.08)
There Is No Halt For First Gold Exploration Inc. (CVE:EFG) Stock
Contributed by: Ekaterina Zelenkova
Date: Sep 16, 2010
http://ca.hotstocked.com/article/2885/there-is-no-halt-for-first-gold-exploration-inc.html
First Gold Exploration Inc....
(TSX VENTURE: EFG) (OTCQX: FGEXF)
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=54465121
Best Drill Results to Date, New Listing and Project Updates
Date : 09/15/2010 @ 10:41AM
Source : MarketWire
Stock : First Gold Exploration Inc. (EFG)
http://ih.advfn.com/p.php?pid=nmona&article=44380934&symbol=TX^EFG
First Gold Exploration Inc. (TSX VENTURE: EFG) (OTCQX: FGEXF) (FRANKFURT: F12) is pleased to report the most recent drill results for the Lac Pivert/Rose project. The table below shows the results for holes LR-10-69 to LR-10-90, drilled to test the extension of the zones to the east. All the holes intersected mineralized zones over consistent thicknesses, and indicated that width and grade are increasing.
The drilling program is ongoing, with Hole LR-10-126 presently underway. Drilling continues to intersect the mineralized zones with sustained thickness.
A map showing the location of the holes is posted under Pivert/Rose Lithium Project in the Projects section of the Company's website, at www.firstgoldexploration.com .
The best results obtained to date are as follows:
--------------------------------------------------------------------------
HOLE TRUE
FROM TO WIDTH Li20 Rb Ta2O5 Be Cs Ga
# ppm ppm ppm ppm ppm
(m) (m) (m) (%) (g/t) (g/t) (g/t) (g/t) (g/t)
--------------------------------------------------------------------------
LR-10-69 89.15 109.20 20.05 1.31 2649 180 113 109 72
--------------------------------------------------------------------------
LR-10-70 91.50 97.00 6.50 0.91 3899 232 121 135 73
--------------------------------------------------------------------------
LR-10-71 48.35 62.45 14.15 1.64 2182 137 124 72 75
--------------------------------------------------------------------------
LR-10-72 37.95 53.20 15.25 1.34 2547 150 72 97 69
--------------------------------------------------------------------------
LR-10-73 39.70 45.80 6.10 0.15 1726 125 127 73 62
--------------------------------------------------------------------------
LR-10-74 20.85 29.00 8.15 0.37 4358 119 143 166 57
--------------------------------------------------------------------------
LR-10-75 52.45 73.90 21.45 1.22 2983 206 139 117 78
--------------------------------------------------------------------------
LR-10-76 11.15 18.70 7.55 1.35 2833 197 148 143 79
--------------------------------------------------------------------------
LR-10-77 34.70 39.00 4.30 1.75 1903 208 118 80 86
--------------------------------------------------------------------------
LR-10-78 49.20 61.70 12.50 1.30 1882 112 141 80 76
--------------------------------------------------------------------------
LR-10-79 59.8 75.65 15.85 1.50 2283 188 143 77 73
--------------------------------------------------------------------------
LR-10-80 66.75 85.5 18.05 1.27 3877 189 175 120 75
--------------------------------------------------------------------------
LR-10-81 87.65 102.8 15.15 0.76 2346 176 117 106 67
--------------------------------------------------------------------------
LR-10-82 82.9 99.25 16.35 1.12 2462 189 147 93 74
--------------------------------------------------------------------------
LR-10-83 100.75 120.45 19.70 1.15 2966 175 138 163 77
--------------------------------------------------------------------------
LR-10-84 111.75 126.05 14.30 1.38 3171 181 141 115 72
--------------------------------------------------------------------------
LR-10-85 114.50 130.60 16.10 1.45 2918 149 137 98 67
--------------------------------------------------------------------------
LR-10-86 118.45 135.25 16.80 1.49 1657 145 101 68 61
--------------------------------------------------------------------------
LR-10-87 81.45 96.10 14.65 1.48 2286 157 104 84 68
--------------------------------------------------------------------------
LR-10-88 74.20 92.30 18.10 1.57 2614 183 129 91 77
--------------------------------------------------------------------------
LR-10-89 77.70 93.85 16.15 1.70 2909 204 131 95 69
--------------------------------------------------------------------------
LR-10-90 75.55 93.55 18.00 1.72 2555 161 110 97 73
--------------------------------------------------------------------------
(i) 1 ppm = 1 g/t
All the samples were sent for analysis in sealed containers to the Chemex laboratory in Val-d'Or by employees of the Company. Chemex is the laboratory used for analysis of all samples from programs on the Lac Pivert/Rose property. The samples are weighed and identified prior to sample preparation. The samples are crushed to 70% minus 2 mm, then separation and pulverized to 85% passing 75 um. All samples are analyzed using ICP-MS, with full analysis for 47 elements.
Stock Listing Update
First Gold is pleased to report that it is now listed on the OTCQX in the US under the stock symbol FGEXF. Consequently, the Company is now able to solicit US firms and send information to the US investor base.
Project Update - Lac Pivert/Rose Rare Metal Property
First Gold is drilling the project based on an open pit model. Unlike most spodumine-bearing dykes in the area, those on the Lac Pivert/Rose project lie parallel to surface, starting at 0 meters and dipping very slightly but steadily downward towards the north and the east.
InnovExplo was retained two months ago to complete a 43-101 property report and a resource estimate for the structures (mineralized zones).
Once it has received these reports, the first of which is due in September 2010 and the second in November 2010, the Company will order a pre-feasibility study and drill to expand this area of interest. It should be noted there are roads and power lines within a 1 km radius of the site.
New showings have been discovered 500 metres and up to 2.5 kilometres away from current project location. Sample grades of up to 4.6% Li2O have been received from the lab for these showings. First Gold will mobilize a drill within the next month to determine the potential of these new showings, test the Pivert showing and to try to build resources on other sectors of the property.
Project Update - San Javier Silver Property
First Gold is preparing a sampling program to begin in November 2010 to determine the location of the drilling campaign.
Results of random surface sampling at San Javier in 2009 yielded high silver values: 12,905 g/t or 376,4 oz/ton silver, 2,439 g/t or 71,2 oz/ton silver, 2,356 g/t or 68,7 oz/ton silver and 816 g/t or 23,8 oz/ton silver. In addition to the unusually high-grade silver and gold mineralization, the veins are also rich in base metals: copper, lead, zinc, tin and iron ore.
A recently-completed positive 43-101 report for the property confirmed that the project has strong exploration potential. Given the recent strength of silver prices, San Javier could grow to be another important asset for the Company.
Jean-Sebastien Lavallee (OGQ #773), a geologist, shareholder and director of the Company and a Qualified Person under NI 43-101, has reviewed and approved the technical content of this release.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
First Gold Exploration Inc.
Eric Leboeuf
President and Chief Executive Officer
450-744-0792
president@firstgoldexploration.com
www.firstgoldexploration.com
First Gold Exploration Inc.
Jean-Sebastien Lavallee, P.Geo
Director and geologist
819-354-5146
jslavallee@consul-teck.com
www.firstgoldexploration.com
RT CAN
Best Drill Results to Date, New Listing and Project Updates
Date : 09/15/2010 @ 10:41AM
Source : MarketWire
Stock : First Gold Exploration Inc. (EFG)
http://ih.advfn.com/p.php?pid=nmona&article=44380934&symbol=TX^EFG
First Gold Exploration Inc. (TSX VENTURE: EFG) (OTCQX: FGEXF) (FRANKFURT: F12) is pleased to report the most recent drill results for the Lac Pivert/Rose project. The table below shows the results for holes LR-10-69 to LR-10-90, drilled to test the extension of the zones to the east. All the holes intersected mineralized zones over consistent thicknesses, and indicated that width and grade are increasing.
The drilling program is ongoing, with Hole LR-10-126 presently underway. Drilling continues to intersect the mineralized zones with sustained thickness.
A map showing the location of the holes is posted under Pivert/Rose Lithium Project in the Projects section of the Company's website, at www.firstgoldexploration.com.
The best results obtained to date are as follows:
--------------------------------------------------------------------------
HOLE TRUE
FROM TO WIDTH Li20 Rb Ta2O5 Be Cs Ga
# ppm ppm ppm ppm ppm
(m) (m) (m) (%) (g/t) (g/t) (g/t) (g/t) (g/t)
--------------------------------------------------------------------------
LR-10-69 89.15 109.20 20.05 1.31 2649 180 113 109 72
--------------------------------------------------------------------------
LR-10-70 91.50 97.00 6.50 0.91 3899 232 121 135 73
--------------------------------------------------------------------------
LR-10-71 48.35 62.45 14.15 1.64 2182 137 124 72 75
--------------------------------------------------------------------------
LR-10-72 37.95 53.20 15.25 1.34 2547 150 72 97 69
--------------------------------------------------------------------------
LR-10-73 39.70 45.80 6.10 0.15 1726 125 127 73 62
--------------------------------------------------------------------------
LR-10-74 20.85 29.00 8.15 0.37 4358 119 143 166 57
--------------------------------------------------------------------------
LR-10-75 52.45 73.90 21.45 1.22 2983 206 139 117 78
--------------------------------------------------------------------------
LR-10-76 11.15 18.70 7.55 1.35 2833 197 148 143 79
--------------------------------------------------------------------------
LR-10-77 34.70 39.00 4.30 1.75 1903 208 118 80 86
--------------------------------------------------------------------------
LR-10-78 49.20 61.70 12.50 1.30 1882 112 141 80 76
--------------------------------------------------------------------------
LR-10-79 59.8 75.65 15.85 1.50 2283 188 143 77 73
--------------------------------------------------------------------------
LR-10-80 66.75 85.5 18.05 1.27 3877 189 175 120 75
--------------------------------------------------------------------------
LR-10-81 87.65 102.8 15.15 0.76 2346 176 117 106 67
--------------------------------------------------------------------------
LR-10-82 82.9 99.25 16.35 1.12 2462 189 147 93 74
--------------------------------------------------------------------------
LR-10-83 100.75 120.45 19.70 1.15 2966 175 138 163 77
--------------------------------------------------------------------------
LR-10-84 111.75 126.05 14.30 1.38 3171 181 141 115 72
--------------------------------------------------------------------------
LR-10-85 114.50 130.60 16.10 1.45 2918 149 137 98 67
--------------------------------------------------------------------------
LR-10-86 118.45 135.25 16.80 1.49 1657 145 101 68 61
--------------------------------------------------------------------------
LR-10-87 81.45 96.10 14.65 1.48 2286 157 104 84 68
--------------------------------------------------------------------------
LR-10-88 74.20 92.30 18.10 1.57 2614 183 129 91 77
--------------------------------------------------------------------------
LR-10-89 77.70 93.85 16.15 1.70 2909 204 131 95 69
--------------------------------------------------------------------------
LR-10-90 75.55 93.55 18.00 1.72 2555 161 110 97 73
--------------------------------------------------------------------------
(i) 1 ppm = 1 g/t
All the samples were sent for analysis in sealed containers to the Chemex laboratory in Val-d'Or by employees of the Company. Chemex is the laboratory used for analysis of all samples from programs on the Lac Pivert/Rose property. The samples are weighed and identified prior to sample preparation. The samples are crushed to 70% minus 2 mm, then separation and pulverized to 85% passing 75 um. All samples are analyzed using ICP-MS, with full analysis for 47 elements.
Stock Listing Update
First Gold is pleased to report that it is now listed on the OTCQX in the US under the stock symbol FGEXF. Consequently, the Company is now able to solicit US firms and send information to the US investor base.
Project Update - Lac Pivert/Rose Rare Metal Property
First Gold is drilling the project based on an open pit model. Unlike most spodumine-bearing dykes in the area, those on the Lac Pivert/Rose project lie parallel to surface, starting at 0 meters and dipping very slightly but steadily downward towards the north and the east.
InnovExplo was retained two months ago to complete a 43-101 property report and a resource estimate for the structures (mineralized zones).
Once it has received these reports, the first of which is due in September 2010 and the second in November 2010, the Company will order a pre-feasibility study and drill to expand this area of interest. It should be noted there are roads and power lines within a 1 km radius of the site.
New showings have been discovered 500 metres and up to 2.5 kilometres away from current project location. Sample grades of up to 4.6% Li2O have been received from the lab for these showings. First Gold will mobilize a drill within the next month to determine the potential of these new showings, test the Pivert showing and to try to build resources on other sectors of the property.
Project Update - San Javier Silver Property
First Gold is preparing a sampling program to begin in November 2010 to determine the location of the drilling campaign.
Results of random surface sampling at San Javier in 2009 yielded high silver values: 12,905 g/t or 376,4 oz/ton silver, 2,439 g/t or 71,2 oz/ton silver, 2,356 g/t or 68,7 oz/ton silver and 816 g/t or 23,8 oz/ton silver. In addition to the unusually high-grade silver and gold mineralization, the veins are also rich in base metals: copper, lead, zinc, tin and iron ore.
A recently-completed positive 43-101 report for the property confirmed that the project has strong exploration potential. Given the recent strength of silver prices, San Javier could grow to be another important asset for the Company.
Jean-Sebastien Lavallee (OGQ #773), a geologist, shareholder and director of the Company and a Qualified Person under NI 43-101, has reviewed and approved the technical content of this release.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
First Gold Exploration Inc.
Eric Leboeuf
President and Chief Executive Officer
450-744-0792
president@firstgoldexploration.com
www.firstgoldexploration.com
First Gold Exploration Inc.
Jean-Sebastien Lavallee, P.Geo
Director and geologist
819-354-5146
jslavallee@consul-teck.com
www.firstgoldexploration.com
RT CAN
Tara Minerals is proposing to - 300,000 oz gold + 8 million ounces of silver for $ 1 million!
http://translate.google.com/translate?langpair=de|en&u=http%3A%2F%2Fwww.goldseiten.de%2Fcontent%2Fdiverses%2Fartikel.php%3Fstoryid%3D14387
http://www.goldseiten.de/content/diverses/artikel.php?storyid=14387
14.09.2010
© Jan Kneist © Jan Kneist
Metals & Mining Consult Ltd. Metals & Mining Ltd. Consult.
Tara Minerals is proposing to - 300,000 oz gold + 8 million ounces of silver for $ 1 million!
http://translate.google.com/translate?langpair=de|en&u=http%3A%2F%2Fwww.goldseiten.de%2Fcontent%2Fdiverses%2Fartikel.php%3Fstoryid%3D14387
http://www.goldseiten.de/content/diverses/artikel.php?storyid=14387
14.09.2010
© Jan Kneist © Jan Kneist
Metals & Mining Consult Ltd. Metals & Mining Ltd. Consult.
Clinical and Preclinical Programs
http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID=1457240&highlight=
IMO-2125, a TLR9 Agonist, in Chronic Hepatitis C Virus (HCV) Infection
* Phase 1 Clinical Trial of IMO-2125 Monotherapy in Null Responder Patients with Chronic HCV Infection
In April 2010, during the 45th Annual Meeting of the European Association for the Study of the Liver (EASL), the Company presented positive interim data from this trial through the dose level of 0.32-mg/kg/week for four weeks, comprising 33 null responder HCV patients treated with IMO-2125 and 8 null responder HCV patients who received placebo treatment. Based on the data presented at EASL, the clinical trial was extended to a fifth cohort at the dosage of 0.48 mg/kg/week for four weeks and recruitment is continuing at this dose level. We also are recruiting a cohort of eight null responder HCV patients to evaluate the safety and the effect on HCV viral load of twice-weekly IMO-2125 administration for four weeks. The clinical trial of IMO-2125 monotherapy in null responder HCV patients is being conducted at multiple sites in the U.S.
The Company expects data from the Phase 1 clinical trial of IMO-2125 monotherapy in null responder HCV patients to be available in the fourth quarter of 2010.
* Phase 1 Clinical Trial of IMO-2125 in Combination with Ribavirin in Treatment-naïve Patients with Chronic HCV Infection
In this clinical trial, treatment-naïve HCV patients receive IMO-2125 by subcutaneous injection once per week for four weeks at escalating dose levels of 0.08, 0.16, and 0.32 mg/kg in combination with daily oral administration of standard doses of ribavirin. The current plans for this trial are to evaluate IMO-2125 plus ribavirin in a total of 48 patients. In addition, a total of 12 patients are planned to receive pegylated recombinant alfa-2a interferon plus ribavirin as the control arm. The primary objective of the trial is to assess the safety and tolerability of IMO-2125 in combination with standard doses of ribavirin. In addition, this trial is designed to monitor the effect of treatment on HCV viral load and on activation of the immune system. The clinical trial is currently being conducted at sites in France and Russia.
The Company expects preliminary data from the Phase 1 clinical trial of IMO-2125 in combination with ribavirin in treatment-naïve HCV patients to be available in the fourth quarter of 2010.
* Plans for Phase 2 Clinical Evaluation of IMO-2125 in Patients with Chronic HCV Infection
The Company has begun preparations for a 12-week Phase 2 clinical trial of IMO-2125 administered in combination with ribavirin to patients with chronic HCV infection towards intended initiation by the end of the year.
IMO-3100, a Dual Antagonist of TLR7 and TLR9, in Autoimmune and Inflammatory Diseases
IMO-3100 has shown activity in various preclinical models of autoimmune and inflammatory diseases, including lupus, rheumatoid arthritis, psoriasis and hyperlipidemia. As a first step in the clinical development of IMO-3100, we are conducting Phase 1 clinical trials in healthy subjects to evaluate safety and mechanism of action prior to the initiation of clinical trials in patients with autoimmune disease.
* Phase 1 Single-Dose, Dose Escalation Clinical Trial of IMO-3100 in Healthy Subjects: Safety and Mechanism of Action
In January 2010, the Company initiated a single-dose, dose escalation, Phase 1 clinical trial of IMO-3100 in healthy subjects. In this trial, six healthy subjects in each of five dosage cohorts received single doses of IMO-3100 from 0.04 to 0.64 mg/kg. Six additional subjects each received a single dose of placebo. The primary objective was evaluation of safety and tolerability. Secondary objectives were to characterize the blood levels of IMO-3100 and to assess the pharmacodynamic mechanism of action through the response of peripheral blood mononuclear cells to agonists of TLR7 and TLR9. The trial was conducted at a single U.S. site.
In June 2010, the Company announced preliminary results from the Phase 1 single-dose, dose escalation clinical trial of IMO-3100. IMO-3100 was well tolerated at all dose levels. Peripheral blood mononuclear cells from subjects who received IMO-3100 showed suppression of immune responses mediated through TLR7 and TLR9. The immune responses monitored included induction of tumor necrosis factor-alpha (TNF-a), interleukin-1 beta (IL-1B), interleukin-6 (IL-6), interferon-alpha (IFN-a), and other pro-inflammatory cytokines. Peripheral blood mononuclear cells from placebo-treated subjects did not show any consistent suppression of immune responses mediated through TLR7 or TLR9.
The Company is planning to present detailed results of the Phase 1 single-dose, dose escalation clinical trial of IMO-3100 in healthy subjects at a scientific meeting in the fourth quarter of 2010.
* Phase 1 Multiple-Dose Clinical Trial of IMO-3100 in Healthy Subjects: Safety and Mechanism of Action
In July 2010, the Company initiated a four-week multiple-dose clinical trial of IMO-3100 in healthy subjects. The purpose of the multiple-dose clinical trial is to evaluate the safety, blood levels of IMO-3100, and pharmacodynamic mechanism of action of IMO-3100 with multiple-dose subcutaneous administration over four weeks. The trial is designed to include 16 subjects treated with IMO-3100 and eight subjects treated with placebo.
The Company expects preliminary data from the Phase 1 multiple-dose clinical trial of IMO-3100 in healthy subjects to be available in the fourth quarter of 2010.
* Plans for Phase 2 Clinical Evaluation of IMO-3100 in Autoimmune Disease
The Company expects that the safety and pharmacodynamic mechanism of action data from the Phase 1 clinical trials in healthy subjects will help move the clinical evaluation of IMO-3100 rapidly into selected autoimmune disease indications. The Company intends to identify an initial autoimmune disease indication for further clinical development of IMO-3100 and to initiate a Phase 2 clinical trial by the end of 2010.
EMD 1201081 (IMO-2055), a TLR9 Agonist, in Cancer Treatment (Collaboration with Merck KGaA)
In December 2007, the Company entered into an exclusive, worldwide license agreement with Merck KGaA to research, develop and commercialize products containing its TLR9 agonists for the treatment of cancer, excluding cancer vaccines. Merck KGaA currently is conducting the following clinical trials of EMD 1201081:
* Phase 2 Clinical Trial of EMD 1201081 in Combination with Erbitux(R) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
* Phase 1b Clinical Trial of EMD 1201081 in Combination with Tarceva(R) and Avastin(R) in Non-small Cell Lung Cancer (NSCLC)
* Phase 1b Clinical Trial of EMD 1201081 in Combination with Erbitux(R) and Chemotherapy in Colorectal Cancer (CRC)
IMO-2134, a TLR9 Agonist, for Respiratory Diseases
During our collaboration with Novartis, IMO-2134 was identified as a lead compound for development in asthma and allergy indications and Novartis initiated a Phase 1 clinical trial of IMO-2134, also known as QAX935. Upon the termination of the research collaboration and option agreement in February 2010, the Company regained the rights to IMO-2134. The Company is currently evaluating the next steps in developing IMO-2134 for respiratory diseases.
TLR7, 8 and 9 Agonists as Vaccine Adjuvants (Collaboration with Merck & Co., Inc.)
In December 2006, the Company and Merck & Co., Inc. (now Merck Sharp & Dohme Corp. and referred to herein as Merck) entered into an exclusive license and research collaboration agreement to research, develop and commercialize vaccine products containing the Company's TLR7, 8, and 9 agonists in the fields of oncology, infectious diseases and Alzheimer's disease. As part of the agreement, the two companies engaged in a research collaboration to generate novel agonists targeting TLR7 and TLR8, incorporating both Merck and Idera chemistry, for use in the licensed fields. In November 2009, Merck extended the research collaboration with the Company for a fourth year to December 2010. Under the terms of the agreement, Merck is funding the research and development activities under the collaboration.
Scientists from Merck and Idera have co-authored the following presentation and publication:
* "Novel TLR9 Agonists Combined with Alum for Use as Vaccine Adjuvants" at the Keystone Symposia Molecular and Cellular Biology conference "Innate Immunity: Mechanisms Linking with Adaptive Immunity" held June 7-12, 2010 in Dublin, Ireland.
* A paper entitled "A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine" in Vaccine, April 2010.
TLR7 and TLR8 Agonists
The Company has created synthetic stabilized immune modulatory RNA (SIMRA) compounds that mimic viral RNA and induce immune responses by functioning as agonists of TLR7 and TLR8. The Company is continuing to study selected dual TLR7 and TLR8 agonists in preclinical models of hematological cancers and has observed antitumor activity of a dual agonist of TLR7 and TLR8 as monotherapy and in combination with selected targeted drugs currently approved for cancer treatment. The Company intends to select a dual TLR7 and TLR8 agonist as a lead drug candidate by the end of the year.
The Company is planning to present preclinical data on its dual agonist of TLR7 and TLR8 in models of hematological cancers at a scientific meeting in the fourth quarter of 2010.
TLR Antisense
The Company has identified antisense compounds targeted to human TLRs 2, 3, 4, 5, 7, 8 and 9 and to the TLR-associated signaling protein MyD88. The Company is studying these compounds for potential applications in autoimmune and inflammatory diseases.
Scientific Highlights
Data Presentations
* An oral presentation, entitled "A Phase 1, Multi-Center, Randomized, Placebo-controlled, Dose-escalation Study of IMO-2125, a TLR9 Agonist, in Hepatitis C Non-responders", was made by John McHutchison, M.D., Associate Director, Duke Clinical Research Institute and Director, Gastroenterology and Hepatology Research, Duke University Medical Center, and Principal Investigator for this trial, at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) held April 14-18, 2010, in Vienna, Austria.
* A presentation, entitled "IMO-2125, an agonist of TLR9 that induces endogenous IFN-alpha, upregulates broader range of gene expression profiles compared to exogenously added IFN-alpha in human PBMCs" was made by Idera scientists at the 45th Annual Meeting of EASL.
* A presentation, entitled "A novel antagonist of TLR7 and TLR9 exerts anti- atherogenic effects in ApoE-/- mouse model of atherosclerosis" was made by Idera scientists at the American Heart Association conference "Arteriosclerosis, Thrombosis and Vascular Biology 2010 Scientific Sessions" held April 8-10, 2010, in San Francisco, CA.
* A presentation, entitled "Synthetic Agonists and Antagonists of
Toll-like Receptor 7, 8 and 9" was made by Idera scientists at the Keystone Symposia Molecular and Cellular Biology conference "Innate Immunity: Mechanisms Linking with Adaptive Immunity" held June 7-12, 2010 in Dublin, Ireland.
Publications
* A paper entitled "Antitumor Activity and Immune Response Induction of a Dual Agonist of Toll-like Receptors 7 and 8" appeared in Molecular Cancer Therapeutics, June 2010.
* A paper entitled "Impact of nature and length of linker incorporated in agonists on Toll-like receptor 9-mediated immune responses" appeared in Journal of Medicinal Chemistry, May 2010.
Intellectual Property
The Company's intellectual property portfolio contains over 500 patents and patent applications worldwide. In June 2010, the Company was again recognized by the Patent Board(TM) as one of the top 35 companies in the biotechnology field based on its technology and intellectual property advances. The Patent Board is an independent group that tracks and analyzes intellectual property and technology assets across 17 industries globally and publishes its results in the Wall Street Journal.
Immune Modulatory Oligonucleotide (IMO(R)) Technology
This portfolio holds over 290 patents and patent applications worldwide covering the Company's IMO technologies and includes claims covering novel agonists of TLRs 7, 8, and 9, and antagonists of TLR7 and TLR9. These patents and patent applications include claims covering IMO-2055, IMO-2125, IMO-2134, and IMO-3100. The Company was granted the following U.S. patents during the second quarter:
* US 7,700,570, entitled "Oligonucleotide Mediated Specific Cytokine Induction and Prophylaxis and Treatment of Viral Infection in a Mammal."
* US 7,709,617, entitled "Synergistic Stimulation of the Immune System Using Immunostimulatory Oligonucleotides and/or Immunomer Compounds in Conjunction with Cytokines and/or Chemotherapeutic Agents or Radiation Therapy."
* US 7,713,535, entitled "Modulation of Immunostimulatory Properties by Small Oligonucleotide-Based Compounds."
In addition to the recently issued U.S. patents, the Company was granted: AU 20044206820, corresponding to U.S. Patent No. 7,632,822, entitled "Modulation of Immunostimulatory Properties of Oligonucleotide-Based Compounds By Using Modified Immunostimulatory Dinucleotides;" AU 2005222909, corresponding to U.S. Patent Application No. 11/078,654, entitled "Enhanced Activity of HIV Vaccine Using a Second Generation Immunomodulatory Oligonucleotide;" AU 20044304770, corresponding to U.S. Patent No. 7,713,535, entitled "Modulation of Immunostimulatory Properties by Small Oligonucleotide-Based Compounds;" and IN 240192, corresponding to U.S. Patent Application No. 10/865,245, entitled "Stabilized Immunomodulatory Oligonucleotides."
Antisense Technology
The Company's antisense technology portfolio includes 210 patents and patent applications worldwide owned or licensed by Idera covering novel antisense compounds and methods of their use. These patents and patent applications include claims covering second-generation antisense chemistry, oral delivery of second-generation antisense compounds, and certain genes, antisense sequences, and therapeutic targets (including various TLRs and signaling molecules).
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances. For more information, visit http://www.iderapharma.com.
Zoom Technologies Receives a Proposal for a Line of Credit of $44 Million From Bank of China
Date : 09/15/2010 @ 12:14PM
Source : MarketWire
Stock : Zoom Technologies (ZOOM)
http://ih.advfn.com/p.php?pid=nmona&article=44383040&symbol=ZOOM
Zoom Technologies, Inc. (NASDAQ: ZOOM), a leading China based manufacturer of mobile phones and related products, today announced that its manufacturing subsidiary, TCB Digital, has been provided a proposal for a line of credit of up to Rmb 300 million (approximately US$44 million) from the Bank of China for the Company. The credit facility, if provided, can allow Zoom Technologies to accelerate manufacturing expansion to support the increase in its EMS (electronics manufacturing services) customer demand.
To make the credit facility available, Zoom Technologies needs to satisfy collateral requirements either based on the real property of the Company's new manufacturing plant that is currently under construction, or by a guarantee from Tianjin Leimone Industrial Co. Ltd. which is an entity controlled by Zoom's Chairman, Mr. Lei Gu. The credit from Bank of China, if approved, would allow Zoom Technologies to borrow up to $44 million on a one-year term, at an annual interest rate equal to the prevailing one-year benchmark lending rate as set by China's central bank which is currently 5.58%.
Mr. Lei Gu, Chairman and Chief Executive Officer of Zoom Technologies, stated, "This proposal to extend credit underscores the confidence that Bank of China has in the future of our business and Zoom's position in the robust China mobile phone market. The credit facility would provide the funds to expand our manufacturing capacity, attract greater customer orders, and increase our market share. The line of credit would strengthen our working capital which would place Zoom in an excellent position to negotiate additional contracts and strategic collaborations on optimal terms for Zoom Technologies and its stockholders. This would allow us to grow with the rapidly expanding China 3G market and produce mobile products for top tier Chinese mobile phone companies."
About Zoom Technologies
Zoom Technologies is a holding company with subsidiaries that engage in the manufacturing, research and development, and sale of electronic and telecommunication products for the latest generation mobile phones, wireless communication circuitry, and related software products. Zoom Technologies' subsidiary, Jiangsu Leimone, owns a majority stake of TCB Digital, which offers highly customized and high quality Electronic Manufacturing Service (EMS) for Original Equipment Manufacturer (OEM) customers as well as its Own Brand Manufacturing (OBM) under the brand name of Leimone. The company's products are both exported and sold domestically.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events which cannot be assured. You should not place undue reliance on these forward-looking statements. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly release revisions to these forward-looking statements to reflect future events or circumstances or reflect the occurrence of unanticipated events.
Contact:
Cynthia Hiponia
The Blueshirt Group
+1 415-217-4966
PDL BioPharma to Present at Upcoming Investor Conferences
Date : 09/15/2010 @ 7:00AM
Source : PR Newswire
Stock : Pdl Biopharma (MM) (PDLI)
http://ih.advfn.com/p.php?pid=nmona&article=44375940&symbol=PDLI
PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the following upcoming conferences.
UBS Global Life Sciences Conference
Tuesday, September 21, 2010
2:30 p.m. ET
New York City
5th Annual JMP Securities Healthcare Conference
Monday, September 27, 2010
9:00 a.m. ET
New York City
To access the live and subsequently archived webcasts of the presentations, go to the Company's website at http://www.pdl.com and go to "Company Presentations & Events." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. The archived webcast will be available for seven days following each presentation.
About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today based on patents which expire in late 2014. For more information, please visit www.pdl.com.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.
SOURCE PDL BioPharma, Inc.
Bruce A. Peacock Joins Discovery Labs' Board of Directors
Date : 09/15/2010 @ 7:00AM
Source : GlobeNewswire Inc.
Stock : Discovery Laboratories, Inc. (DSCO)
http://ih.advfn.com/p.php?pid=nmona&article=44375905
Discovery Laboratories, Inc. (Nasdaq:DSCO), a biotechnology company developing its novel, synthetic, peptide-containing surfactant and related aerosolization technologies as first-in-class therapies for severe respiratory diseases, today announced that Bruce A. Peacock has joined the Company's Board of Directors. With Mr. Peacock's appointment, Discovery Labs has expanded its Board of Directors to six members
W. Thomas Amick, Chairman of the Board and Interim Chief Executive Officer, commented, "Bruce has an excellent and long-standing reputation in the life science industry, and brings a wealth of experience and proven track record of success to Discovery. As a CEO, COO and CFO for several biotechnology companies, Bruce has provided his executive leadership to advance research and development operations into successful, high growth commercial biopharmaceutical organizations. His expertise will be invaluable to our Board."
Mr. Peacock commented, "Discovery has the potential to build a significant respiratory company based in its promising surfactant and aerosolization technologies. I am excited about joining the Board to help guide the Company and provide strategic input to management as we work towards the potential approval of Surfaxin® for the prevention of Respiratory Distress Syndrome (RDS) in premature infants and advance the Surfaxin LS™ and Aerosurf® programs for RDS to the clinic."
Since 2006, Mr. Peacock, age 59, has served as a Venture Partner with SV Life Sciences Advisors, LLC, and since 2009, as President, Chief Executive Officer and Director of Alba Therapeutics. Mr. Peacock began his career in biotechnology in 1982 at Centocor, Inc. Serving as Chief Financial Officer, he was part of a team that raised over $850 million in debt, equity capital and alliances and received multiple product regulatory approvals. In 1992, Mr. Peacock joined Cephalon, Inc., and as Executive Vice President, Chief Operating Officer and Director, had responsibility for corporate development, finance and administration, commercial and manufacturing operations, and managed the successful launch of Provigil®, Cephalon's first proprietary product with annual sales currently approaching $1 billion. In 1999, Mr. Peacock joined Orthovita, Inc., a public orthopaedic biomaterials company, where during his tenure as President, Chief Executive Officer and Director, the company received regulatory approval for four products and launched its commercial sales effort. From 2002 to 2005, he served as President, Chief Executive Officer and Director of Adolor Corporation, a public biotechnology Company. During his tenure, he led efforts leading to the acceptance of the company's first New Drug Application and established the company's first commercial organization. Prior to joining SV Life Sciences, he was Chief Executive Officer and director of The Little Clinic, a medical care services company. Mr. Peacock earned a bachelor's degree in Business Administration from Villanova and is a certified public accountant.
About Discovery Labs
Discovery Laboratories, Inc. is a biotechnology company developing KL4 surfactant therapies for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, aerosol or lyophilized formulations. In addition, Discovery Labs' proprietary capillary aerosolization technology produces a dense aerosol, with a defined particle size that is capable of potentially delivering aerosolized KL4 surfactant to the deep lung without the complications currently associated with liquid surfactant administration. Discovery Labs believes that its proprietary technology platform makes it possible, for the first time, to develop a significant pipeline of surfactant products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.Discoverylabs.com.
Forward Looking Statements
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including with respect to the potential approval in the United States of Surfaxin for the prevention of RDS in premature infants, are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Examples of such risks and uncertainties are described in Discovery Labs' filings with the Securities and Exchange Commission including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.
CONTACT: Linnden Communications
Media Relations:
Michelle Linn
508-362-3087
Discovery Laboratories, Inc.
Investor Relations:
John G. Cooper, President and Chief Financial Officer
215-488-9490
Tara Minerals Reaches Agreement to Acquire Tara Gold Resources for $83 Million
Date : 09/13/2010 @ 2:00AM
Source : MarketWire
Stock : Tara Minerals Corp. (TRGD)
Tara Minerals Corp. (OTCBB: TARM) (BERLIN: 6T3) and Tara Gold Resources Corp. (PINKSHEETS: TRGD) (FRANKFURT: T8N) have entered into a tentative agreement for Tara Minerals to acquire all of the common shares of Tara Gold in a transaction valued at approximately US $83 million (the "Transaction"). Pursuant to the definitive agreement, two (2) Tara Gold shares will be exchanged for one (1) Tara Minerals share. The Transaction implies a purchase price of US $0.805 per Tara Gold share, representing a premium of 125% over the closing market price of TRGD as of September 10, 2010. The Transaction has been unanimously approved by the Board of Directors of each of Tara Minerals and Tara Gold.
Tara Gold currently owns 40,897,440 shares of Tara Minerals, representing approximately US $66 million of the Transaction value. These shares will be cancelled upon closing of the Transaction. In addition to the Tara Minerals shares, Tara Gold also has the following assets.
* La Currita Mine - La Currita is a past producing gold/silver project which borders the southeast end of Coeur's Guadalupe deposit (producing 7.9 million ounces of silver in 2010) in the south end of the Palmarejo District. A mineralized structure is exposed on surface for about 1 km, with 6 developed levels and samples returning up to 5 g/t gold and 600 g/t silver. La Currita has the potential for a near-term production scenario.
* Las Minitas - The property lies at the western edge of the Sierra Madre Occidental gold/silver belt where a number of successful gold/silver exploration projects are ongoing. Exploration suggests that a mineralization corridor may exist that covers a minimum 3 km strike length, is 100 m wide and is believed to extend for at least 10 km.
* 2.5 million shares in NWM Mining Corp. - NWM Mining is a public Canadian mineral exploration company focused on the development of the Lluvia de Oro / La Jojoba gold mine located in Sonora in North West Mexico. To date, the mine has a Proven + Probable Reserves of 384,361 ounces gold. Gold/silver/copper mining operations have begun. Tara may earn an additional 2.5 million shares upon NWM reaching a pre-defined production target. Tara Gold sold the Lluvia de Oro project to NWM.
* 1.5 million shares in La Camera Mining Inc. - La Camera is a private company that is exploring its Morelos project (adjacent to Goldcorp) in Mexico. La Camera has intercepted mineralization and is working towards defined resources. Senior producers have shown interest in the project.
* Loan to Tara Minerals - Tara Minerals has debt owing to Tara Gold in the amount of US $1.5 million. This will be cancelled upon closing of the Transaction.
Tara Gold and Tara Minerals management has recommended that their shareholders support the Transaction. The Transaction requires the approval of non-affiliate shareholders owning a majority of the outstanding shares of Tara Minerals and Tara Gold. The Transaction is expected to be completed in 2010. Shareholders with questions on the Transaction may contact the company in the US at (888) 901-4550 or in Germany at 021-53-91-04846.
Mr. Francis Biscan Jr., President of Tara Minerals Corp., commented, "The Transaction delivers significant value to all shareholders through risk diversification and cost-reducing synergies. It also creates a North American producer with significant growth potential."
About Tara Minerals Corp. (OTCBB: TARM) (BERLIN: 6T3)
Tara Minerals Corp. is generating cash from the sale of Silver, Zinc, and Lead concentrate from its Don Roman mine and mill, located in Choix, Mexico. Management is focused on creating long-term shareholder value as this capital is deployed to increase throughput, enhance resources, further outline new discoveries/targets, and acquire additional strategic assets. Tara's strength in recognizing value early and strategy of reducing risk through a foundation of cash flow, positions it for low-risk value creation.
About Tara Gold Resources Corp. (PINKSHEETS: TRGD) (FRANKFURT: T8N)
Since its inception, Tara Gold has been focused on assembling a pipeline of high-quality precious and non-precious metals projects with potential for economic commercial value. To date, it has added value and profitably sold the San Miguel silver/gold project, and the Lluvia de Oro gold/silver/copper project. Tara Gold currently holds equity positions in La Camera Mining Inc. (a private mining company), NWM Mining Corporation (a public mining company going into production) and a majority position (40.9 million shares) in Tara Minerals Corp. (currently producing silver/zinc/lead and residual gold). Tara Gold also continues to hold several prospective projects, including a past gold/silver producer.
Websites: www.TaraMinerals.com, www.TaraGoldResources.com
IR Contact: David Barefoot - US (888) 901-4550, Germany 021-53-91-0486
Statements in this document regarding the Transaction, the expected timetable for completing the Transaction, benefits and synergies of the Transaction, future opportunities for the combined company, expectations regarding the value and benefits of the Transaction and any other statements about Tara Minerals or Tara Gold managements' future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "anticipates," "expects," estimates and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including, but not limited to: the ability of the parties to consummate the Transaction and satisfy the conditions thereunder; the ability to obtain, and the timing of, the necessary exchange, regulatory and shareholder or stockholder approvals for the Transaction; the impact of any actions taken by any other party to complicate, delay or prevent the Transaction; the ability to realize the anticipated synergies and benefits from the Transaction and the combined company; and the other factors described in Tara Minerals' Annual Report and Annual Information Form on Form 10-K for the year ended December 31, 2009 and its most recent quarterly reports filed with the SEC available on www.sec.gov and Tara Gold's filings with the SEC available on www.sec.gov. Except as required by applicable law, each of Tara Minerals and Tara Gold disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this document.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained herein which are not historical are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies or products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.
Websites:
www.TaraMinerals.com
www.TaraGoldResources.com
IR Contact:
David Barefoot
US (888) 901-4550
Germany 021-53-91-0486
Tara Minerals Reaches Agreement to Acquire Tara Gold Resources for $83 Million
Date : 09/13/2010 @ 2:00AM
Source : MarketWire
Stock : Tara Minerals Corp. (TRGD)
Tara Minerals Corp. (OTCBB: TARM) (BERLIN: 6T3) and Tara Gold Resources Corp. (PINKSHEETS: TRGD) (FRANKFURT: T8N) have entered into a tentative agreement for Tara Minerals to acquire all of the common shares of Tara Gold in a transaction valued at approximately US $83 million (the "Transaction"). Pursuant to the definitive agreement, two (2) Tara Gold shares will be exchanged for one (1) Tara Minerals share. The Transaction implies a purchase price of US $0.805 per Tara Gold share, representing a premium of 125% over the closing market price of TRGD as of September 10, 2010. The Transaction has been unanimously approved by the Board of Directors of each of Tara Minerals and Tara Gold.
Tara Gold currently owns 40,897,440 shares of Tara Minerals, representing approximately US $66 million of the Transaction value. These shares will be cancelled upon closing of the Transaction. In addition to the Tara Minerals shares, Tara Gold also has the following assets.
* La Currita Mine - La Currita is a past producing gold/silver project which borders the southeast end of Coeur's Guadalupe deposit (producing 7.9 million ounces of silver in 2010) in the south end of the Palmarejo District. A mineralized structure is exposed on surface for about 1 km, with 6 developed levels and samples returning up to 5 g/t gold and 600 g/t silver. La Currita has the potential for a near-term production scenario.
* Las Minitas - The property lies at the western edge of the Sierra Madre Occidental gold/silver belt where a number of successful gold/silver exploration projects are ongoing. Exploration suggests that a mineralization corridor may exist that covers a minimum 3 km strike length, is 100 m wide and is believed to extend for at least 10 km.
* 2.5 million shares in NWM Mining Corp. - NWM Mining is a public Canadian mineral exploration company focused on the development of the Lluvia de Oro / La Jojoba gold mine located in Sonora in North West Mexico. To date, the mine has a Proven + Probable Reserves of 384,361 ounces gold. Gold/silver/copper mining operations have begun. Tara may earn an additional 2.5 million shares upon NWM reaching a pre-defined production target. Tara Gold sold the Lluvia de Oro project to NWM.
* 1.5 million shares in La Camera Mining Inc. - La Camera is a private company that is exploring its Morelos project (adjacent to Goldcorp) in Mexico. La Camera has intercepted mineralization and is working towards defined resources. Senior producers have shown interest in the project.
* Loan to Tara Minerals - Tara Minerals has debt owing to Tara Gold in the amount of US $1.5 million. This will be cancelled upon closing of the Transaction.
Tara Gold and Tara Minerals management has recommended that their shareholders support the Transaction. The Transaction requires the approval of non-affiliate shareholders owning a majority of the outstanding shares of Tara Minerals and Tara Gold. The Transaction is expected to be completed in 2010. Shareholders with questions on the Transaction may contact the company in the US at (888) 901-4550 or in Germany at 021-53-91-04846.
Mr. Francis Biscan Jr., President of Tara Minerals Corp., commented, "The Transaction delivers significant value to all shareholders through risk diversification and cost-reducing synergies. It also creates a North American producer with significant growth potential."
About Tara Minerals Corp. (OTCBB: TARM) (BERLIN: 6T3)
Tara Minerals Corp. is generating cash from the sale of Silver, Zinc, and Lead concentrate from its Don Roman mine and mill, located in Choix, Mexico. Management is focused on creating long-term shareholder value as this capital is deployed to increase throughput, enhance resources, further outline new discoveries/targets, and acquire additional strategic assets. Tara's strength in recognizing value early and strategy of reducing risk through a foundation of cash flow, positions it for low-risk value creation.
About Tara Gold Resources Corp. (PINKSHEETS: TRGD) (FRANKFURT: T8N)
Since its inception, Tara Gold has been focused on assembling a pipeline of high-quality precious and non-precious metals projects with potential for economic commercial value. To date, it has added value and profitably sold the San Miguel silver/gold project, and the Lluvia de Oro gold/silver/copper project. Tara Gold currently holds equity positions in La Camera Mining Inc. (a private mining company), NWM Mining Corporation (a public mining company going into production) and a majority position (40.9 million shares) in Tara Minerals Corp. (currently producing silver/zinc/lead and residual gold). Tara Gold also continues to hold several prospective projects, including a past gold/silver producer.
Websites: www.TaraMinerals.com, www.TaraGoldResources.com
IR Contact: David Barefoot - US (888) 901-4550, Germany 021-53-91-0486
Statements in this document regarding the Transaction, the expected timetable for completing the Transaction, benefits and synergies of the Transaction, future opportunities for the combined company, expectations regarding the value and benefits of the Transaction and any other statements about Tara Minerals or Tara Gold managements' future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "anticipates," "expects," estimates and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including, but not limited to: the ability of the parties to consummate the Transaction and satisfy the conditions thereunder; the ability to obtain, and the timing of, the necessary exchange, regulatory and shareholder or stockholder approvals for the Transaction; the impact of any actions taken by any other party to complicate, delay or prevent the Transaction; the ability to realize the anticipated synergies and benefits from the Transaction and the combined company; and the other factors described in Tara Minerals' Annual Report and Annual Information Form on Form 10-K for the year ended December 31, 2009 and its most recent quarterly reports filed with the SEC available on www.sec.gov and Tara Gold's filings with the SEC available on www.sec.gov. Except as required by applicable law, each of Tara Minerals and Tara Gold disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this document.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained herein which are not historical are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies or products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.
Websites:
www.TaraMinerals.com
www.TaraGoldResources.com
IR Contact:
David Barefoot
US (888) 901-4550
Germany 021-53-91-0486
Update: Cytosorbents (OTC: CTSO) nearing several key milestones
Written by Brian Thomson
Wednesday, 15 September 2010 01:00
http://biomedreports.com/articles/most-popular/54143-update-cytosorbents-otc-ctso-nearing-several-key-milestones.html
Dr. Phillip Chan, Chief Executive Officer, of CytoSorbents Corporation (OTCBB:CTSO) presented at the 12th Annual Healthcare Conference at the Rodman & Renshaw Global Investment Conferenceand on Tuesday afternoon and updated the investment community on its clinical program.
Among other things, the company has reached nearly 80% completion of its clinical trial being conducted in Germany for the treatment of severe sepsis. With over 600 human treatments, 250 of which were septic, and no serious device related affects Cytosorb appears to be effective. Additionally, Dr. Chan reiterated that he expects the pivotal trial to be completed in 2010 with CE Mark approval coming in early 2011. This of course would be a major inflection point for the company which would move from a development stage to a fully operational commercial company.
Partnership rumors have also begun to swirl as Dr. Chan discussed recent developments at several key investment conferences in August.
Of particular interest was the military’s interest in the company’s flagship device at the Advanced Technology Applications for Combat Casualty Care (ATACCC) and Force Health Protection Conference (FHP). Due to the fact that many GIs die from sepsis shock resulting from combat related injuries (infection, burn wounds, etc), Dr. Chan believes Cytosorb could be a life saving device for active soldiers overseas.
Dr. Chan also updated investors concerning the company’s production plans upon CE Mark approval. Germany, the third largest medical device market, would be their primary focus. Currently, the company is in discussions with several major distributors in Germany. With limited competition and enough production capacity to meet initial demand, Dr. Chan believes Cytosorb would have widespread acceptance and rapid penetration across Europe.
Once CE Mark approval is obtained, the company plans to begin a trial in the USA in 2011 in hopes of securing FDA approval. According to Dr. Chan, this trial would involve around 300-500 patients, cost between $8-12 million and would likely be funded by a strategic partner.
These two markets together represent a total of $10-$15 billion in annual spending. And with Cytosorb’s prestigious management team, unique approach, near term commercialization, 27 unique patents and highly profitable “razor/razorblade” business model, the company is set to take a major chunk of it.
In regards to shareholders, a number of key milestones are approaching which could impact shareholder value significantly. These include:
1. Successful completion of the pivotal European trial
2. Strategic partnership with big Pharma and possibly other third parties
3. CE Mark Approval
Together, these milestones could result in positive gains for shareholders of a company currently only valued at only $8.5 million.
MDW - QwikReport
http://www.midwaygold.com/s/QwikReport.asp
Apricus Biosciences Announces Pre-Clinical Results Showing the Ability of the NexACT® Technology to Rectal Delivery of Biologics, such as Human Antibodies
Date : 09/14/2010 @ 9:50AM
Source : Business Wire
Stock : Apricus Biosciences (APRI)
http://ih.advfn.com/p.php?pid=nmona&article=44361480&symbol=APRI
Apricus Biosciences (“Apricus Bio,” formerly NexMed, Inc.) (Nasdaq: APRI), backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, today announced results from a pre-clinical pharmacokinetic study showing the ability of NexACT to enable rectal delivery of biologics, such as human antibodies. Specifically, data from the study showed that rectal delivery of Rituxan®, formulated with NexACT, yielded similar blood levels of the antibody, as compared to delivery via subcutaneous route.
Rituxan is currently marketed by Genentech and Biogen IDEC. The drug is prescribed to treat Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL) and Rheumatoid Arthritis (RA) and is delivered either subcutaneously or via three cycles of intravenous infusions in a hospital setting.
Commenting on today’s news, Bassam Damaj, Ph.D., President and Chief Executive Officer of Apricus Bio, stated, “The results of this early stage study are highly encouraging. This is the only rectal delivery technology that we are aware of that can deliver systemic, fully humanized antibodies in levels comparable to those obtained via the subcutaneous delivery route. These pre-clinical results further demonstrate the versatility and potential of the NexACT technology as a multi-route delivery vehicle. A successful reformulation of Rituxan via rectal administration could thereby provide patients the benefit of avoiding painful intravenous infusions and risks of systemic infection. It could also offer the potential of at-home administration.”
About Apricus Biosciences
Backed by NexMed, USA and Bio-Quant, Inc., its revenue generating CRO business, Apricus Bio has leveraged the flexibility of its proven NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth is expected to be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. For further information on Apricus Bio and its subsidiaries, visit http://www.apricusbio.com. (Apricus Bio was previously named NexMed, Inc. The corporate name was changed in September 2010 in recognition of the evolution and expansion of the Company’s business.)
Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including but not limited to, its ability to replicate pre-clinical results in human clinical trials, the ability to obtain necessary rights to use other parties’ compounds with the NexACT technology and the ability to realize growth plans through the out-licensing of our drug candidates or the NexACT technology. Readers are cautioned not to place undue reliance on these forward-looking statements and are urged to read the Company’s risk factors contained in its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, as filed with the SEC.
Morgan Stanley Global Healthcare Unplugged Conference
Tuesday, September 14, 2010
3:55 p.m. Eastern time
New York City
http://finance.yahoo.com/news/PDL-BioPharma-to-Present-at-prnews-931969264.html?x=0&.v=1
Board Name/Ticker Change ...done!
Sunesis to Present at the UBS Global Life Sciences Conference
Date : 09/14/2010 @ 7:30AM
Source : MarketWire
Stock : Sunesis Pharmaceuticals, Inc. (SNSS)
http://ih.advfn.com/p.php?pid=nmona&article=44358052&symbol=N^SNSS
Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will be presenting at the UBS Global Life Sciences Conference on Tuesday, September 21, 2010 at 1:30 P.M. Eastern Time at the Grand Hyatt New York.
A live webcast of this presentation will be available on the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.
SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.
Investor and Media Inquiries:
David Pitts
Argot Partners
212-600-1902
Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717
Corporate Presentation & CEO Interview
http://www.apricusbio.com/
Apricus Bio To Present at the Rodman & Renshaw 12th Annual Healthcare Conference
http://www.apricusbio.com/media_09142010.html
Rodman & Renshaw Annual Global Investment Conference NYC
SAN DIEGO-- (BUSINESS WIRE)-- Apricus Bio, Inc. (Nasdaq: APRI), backed by a revenue generating CRO business and seeking to leverage its proprietary, multi-route NexACT® drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, today announced that Dr. Bassam Damaj, President and Chief Executive Officer, will present at the Rodman & Renshaw 12th Annual Healthcare Conference at 10:25am ET on Tuesday, September 14, 2010, in the Winslow Salon on the 5th floor of the New York Palace Hotel in New York City.
The Company's presentation will be available via webcast and can be accessed at: http://www.wsw.com/webcast/rrshq18/nexm.
About Apricus Bio, Inc.
Backed by a solid, revenue generating CRO business, Apricus Bio has leveraged the flexibility of its proven NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth will be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. For further information on Apricus Bio and its subsidiaries, visit the following websites: www.apricusbio.com and www.bio-quant.com.
Apricus Bio Contacts:
Apricus Bio Investor Relations:
Paula Schwartz
Apricus Bio, Inc. Rx Communications Group, LLC
(917) 322-2216
pschwartz@rxir.com
Apricus Bio, Inc.
Edward Cox, V.P.
Investor Relations & Corporate Development Apricus Bio, Inc.
(858) 926-5811
ecox@ApricusBio.com
RPRX
Upcoming Event - September 2010
Rodman & Renshaw 12th Annual Healthcare Conference
September 14, 2010, 5:45 p.m. - 6:10 p.m. Eastern
The New York Palace Hotel, New York City
http://www.reprosrx.com/investors_events.php
Presentation at the Rodman & Renshaw 12th Annual Healthcare Conference
On September 13, 2010, PDL BioPharma, Inc. (the “Company”) will make a presentation at the Rodman & Renshaw 12th Annual Healthcare Conference in New York City, New York. A copy of the Company’s presentation materials has been posted to the Company’s website and is attached hereto as Exhibit 99.1.
LINK: http://phx.corporate-ir.net/phoenix.zhtml?c=100463&p=irol-SECText&TEXT=aHR0cDovL2lyLmludC53ZXN0bGF3YnVzaW5lc3MuY29tL2RvY3VtZW50L3YxLzAwMDExNDQyMDQtMTAtMDQ5MDgyL3htbA%3d%3d
---
LINK: http://phx.corporate-ir.net/phoenix.zhtml?c=100463&p=irol-secText&TEXT=aHR0cDovL2lyLmludC53ZXN0bGF3YnVzaW5lc3MuY29tL2RvY3VtZW50L3YxLzAwMDExNDQyMDQtMTAtMDQ5MDgyL3htbC9zdWJkb2N1bWVudC8y
PDL BioPharma says responded on Aug 31 that Genentech's assertions on patent infringement were without merit-SEC filing
2010-09-13 21:01 (UTC)
http://www.xe.com/news/2010/09/13/1391489.htm?utm_source=RSS&utm_medium=TL&utm_content=NOGEO&utm_campaign=News_RSS_A
Sept 13 (Reuters) - PDL BioPharma Inc:
* Says responded on August 31 that genentech's assertions on patent
infringement were without merit
* Says filed suit against genentech in nevada to enforce rights under 2003
settlement deal - SEC filing
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here)
COPYRIGHT
Copyright Thomson Reuters 2010. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Upcoming Event
Cardium to Present at the Rodman & Renshaw 12th Annual Healthcare Investment Conference
09.09.2010 15:30
http://www.finanznachrichten.de/nachrichten-2010-09/17918320-cardium-to-present-at-the-rodman-renshaw-12th-annual-healthcare-investment-confe
SAN DIEGO, Sept. 9 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) announced today that Christopher J. Reinhard, Cardium's Chairman and Chief Executive Officer will present at the Rodman&Renshaw 12th Annual Healthcare Investment Conference on September 14, 2010 at 4:55 p.m. Eastern Time. The conference, which will feature more than 500 presenting companies and 3,500 attendees, is being held September 12-15, 2010 at the New York Palace Hotel in New York. A webcast of the Company's presentation will be available live and by replay and can be accessed at http://www.wsw.com/webcast/rrshq18/cxm/ or the Investors section of Cardium's website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-calendar. The investor presentation slides are available and can be viewed at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.
(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO) About Cardium
Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations. Cardium's investment portfolio includes the Tissue Repair Company and Cardium Biologics, medical technology companies primarily focused on the development of innovative therapeutic products for wound healing, bone repair, and cardiovascular indications. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at http://www.cardiumthx.com/.
Copyright 2010 Cardium Therapeutics, Inc. All rights reserved. For Terms of Use Privacy Policy, please visit http://www.cardiumthx.com/. Cardium Therapeutics(TM) and Generx® and MedPodium(TM) are trademarks of Cardium Therapeutics, Inc. Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM), Excellagen(TM), Excellarate(TM) and Osteorate(TM)are trademarks of Tissue Repair Company.
Photo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO
AP Archive: http://photoarchive.ap.org/
http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO
PRN Photo Desk, photodesk@prnewswire.com
Cardium Therapeutics
CONTACT: Bonnie Ortega, Director, Investor/Public Relations of Cardium
Therapeutics, Inc., +1-858-436-1018, InvestorRelations@cardiumthx.com
Web Site: http://www.cardiumthx.com/
© 2010 PR Newswire
PDL BioPharma Provides Clarification Regarding Redemption of Its 2.75% Convertible Subordinated Notes
Date : 09/10/2010 @ 3:14PM
Source : PR Newswire
Stock : Pdl Biopharma (MM) (PDLI)
http://ih.advfn.com/p.php?pid=nmona&article=44326924&symbol=N^PDLI
PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) affirmed that on September 15, 2010 it will redeem all of the Company's outstanding 2.75% Convertible Subordinated Notes, due August 16, 2023 (the "2023 Notes"). Holders of the 2023 Notes have been provided notice of the redemption by the trustee for the Notes.
Those 2023 Note holders who elect to convert their 2023 Notes into the Company's common stock on or before September 14, 2010, rather than have their 2023 Notes redeemed, will be stockholders of record for the Company's October 1, 2010 dividend payment of $0.50 per share of common stock. Such 2023 Note holders will receive the dividend even though they will have converted their notes after the ex-dividend date of September 13, 2010. The conversion rate for the 2023 Notes is 177.1594 shares of common stock per $1,000 principal amount or $5.64 per share.
About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today based on patents that expire in late 2014. For more information, please visit www.pdl.com.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.
Forward-looking Statements
The foregoing statements regarding PDL's intentions with respect to the cash special dividend payment described above are forward-looking statements under the Private Securities Litigation Reform Act of 1995, and actual results could vary materially from the statements made. PDL's ability to pay the special dividend described above is subject to various risks, many of which are outside its control, including prevailing conditions in the capital markets, the continued strength of its royalty assets and other risks and uncertainties as detailed from time to time in the reports filed by PDL with the Securities and Exchange Commission.
SOURCE PDL BioPharma, Inc.
Rodman & Renshaw Annual Global Investment Conference
Monday, September 13, 2010
4:30 p.m. Eastern time
New York City
http://finance.yahoo.com/news/PDL-BioPharma-to-Present-at-prnews-931969264.html?x=0&.v=1
CEL-SCI’s trial will be conducted in nine countries and is expected to be the largest clinical study of head and neck cancer ever conducted. It will also be the first trial in which immunotherapy will be administered before any other traditional means of care are attempted.
http://ih.advfn.com/p.php?pid=nmona&article=44343523&symbol=CVM
CEL-SCI Corp. Receives Approval from North Mississippi Health Services’ Institutional Review Board to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer
Date : 09/13/2010 @ 9:45AM
Source : Business Wire
Stock : CEL-SCI Corporation (CVM)
http://ih.advfn.com/p.php?pid=nmona&article=44343523&symbol=CVM